Back to top
more

LifeStance Health Group (LFST)

(Delayed Data from NSDQ)

$5.04 USD

5.04
1,349,176

-0.06 (-1.18%)

Updated Jul 10, 2024 04:00 PM ET

After-Market: $5.03 -0.01 (-0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Down -8.97% in 4 Weeks, Here's Why You Should You Buy the Dip in LifeStance Health (LFST)

The heavy selling pressure might have exhausted for LifeStance Health (LFST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

LifeStance Health Group (LFST) Reports Q1 Loss, Tops Revenue Estimates

LifeStance Health (LFST) delivered earnings and revenue surprises of 33.33% and 0.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

RadNet (RDNT) Q1 Earnings and Revenues Surpass Estimates

RadNet (RDNT) delivered earnings and revenue surprises of 177.78% and 2.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates

LifeStance Health (LFST) delivered earnings and revenue surprises of -33.33% and 6.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

LifeStance Health (LFST) Soars 6.6%: Is Further Upside Left in the Stock?

LifeStance Health (LFST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Will LifeStance Health Group (LFST) Report Negative Earnings Next Week? What You Should Know

LifeStance Health (LFST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Option Care (OPCH) Q3 Earnings and Revenues Surpass Estimates

Option Care (OPCH) delivered earnings and revenue surprises of 6.90% and 0.07%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

LifeStance Health Group (LFST) Reports Q2 Loss, Tops Revenue Estimates

LifeStance Health (LFST) delivered earnings and revenue surprises of -44.44% and 1.93%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

The Pennant Group, Inc. (PNTG) Tops Q2 Earnings and Revenue Estimates

The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of 12.50% and 5%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

DaVita HealthCare (DVA) Q2 Earnings and Revenues Top Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 25.30% and 1.93%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Option Care (OPCH) Q2 Earnings and Revenues Surpass Estimates

Option Care (OPCH) delivered earnings and revenue surprises of 186.36% and 0.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Option Care (OPCH) Moves 5.2% Higher: Will This Strength Last?

Option Care (OPCH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

LifeStance Health Group (LFST) Reports Q1 Loss, Tops Revenue Estimates

LifeStance Health (LFST) delivered earnings and revenue surprises of 18.18% and 2.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Elanco Animal Health Incorporated (ELAN) Q1 Earnings and Revenues Beat Estimates

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 55.17% and 5.70%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ATI Physical Therapy, Inc. (ATIP) Reports Q1 Loss, Tops Revenue Estimates

ATI Physical Therapy, Inc. (ATIP) delivered earnings and revenue surprises of -87.50% and 4.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare (ADUS) Beats Q1 Earnings and Revenue Estimates

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 7.78% and 1.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in LifeStance Health (LFST): Can Its 5.5% Jump Turn into More Strength?

LifeStance Health (LFST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates

LifeStance Health (LFST) delivered earnings and revenue surprises of 0% and 6.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

LifeStance Health Group (LFST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

LifeStance Health (LFST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chemed (CHE) Tops Q4 Earnings and Revenue Estimates

Chemed (CHE) delivered earnings and revenue surprises of 1.70% and 0.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) Surpasses Q4 Earnings and Revenue Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 12.62% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights Option Care Health, LifeStance Health, Addus HomeCare and Pennant

Option Care Health, LifeStance Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.

4 Stocks to Watch Amid a Challenging Outpatient Home Health Industry

Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. OPCH, LFST, ADUS and PNTG are well poised to gain from the prospects.

LifeStance Health Group (LFST) Reports Q3 Loss, Lags Revenue Estimates

LifeStance Health (LFST) delivered earnings and revenue surprises of 26.67% and 0.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Oak Street Health, Inc. (OSH) Reports Q3 Loss, Tops Revenue Estimates

Oak Street Health, Inc. (OSH) delivered earnings and revenue surprises of 11.11% and 1%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?